Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
May 19 2021 - 7:30AM
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, today announced that
PTX-35 will be featured in several presentations and panel
discussions at the 3rd Annual Treg Directed Therapies Summit on May
19-20. PTX-35 is a novel, potential first-in-class antibody
modulating TNFRSF25 (death receptor 3 or DR3), a receptor that is
preferentially expressed by antigen-experienced T-cells.
- On Wednesday, May 19th at 4PM EDT, Heat Biologics will
present: “A Novel TNFRSF25-Agonist for Regulatory T-Cell
Expansion.” The presenter, Matthew Seavey, Ph.D., Heat Biologics’
Executive Director of Special Projects, plans to discuss how
TNFRSF25-engagement by PTX-35 can expand regulatory T-cells in vivo
and reduce disease severity in several animal models of GVHD &
inflammatory disease.
- On Thursday, May 20th at 3:30PM EDT, Robert B. Levy, Ph.D.,
Professor of Microbiology and Immunology at the University of Miami
Miller School of Medicine, will present: “Improving Outcomes of
Allo-HCT: Manipulating the Regulatory Cell Compartment in vivo to
Ameliorate GVHD.”
- Dr. Seavey will also chair two panels, including: “Exploring
Key Questions to Advance Understanding of Treg Behavior,” and
“Maximizing Immune Tolerance through Generation of Antigen Specific
Tregs.”
The 3rd Annual Treg Directed Therapies
Summit is focused on targeting and translating Treg modifying
therapies and brings together executives and leading researchers
from large pharma, biotech and academia to discuss developments in
Treg therapies.
About PTX-35PTX-35 is a novel,
potential first-in-class antibody modulating TNFRSF25 (death
receptor 3 or DR3), a receptor that is preferentially expressed by
antigen-experienced T-cells. PTX-35 is currently enrolling in a
Phase 1 clinical trial for the treatment of patients with solid
tumors.
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, and a COVID-19
vaccine program in preclinical development. In addition, Heat
Biologics is also developing a pipeline of proprietary
immunomodulatory antibodies and cell-based therapies, including
PTX-35 and HS-130 in Phase 1 clinical trials.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements such as the planned presentations. These
statements are subject to a number of risks and uncertainties, many
of which are difficult to predict, including the contributions of,
the ability of Heat's therapies to perform as designed, to
demonstrate safety and efficacy, as well as results that are
consistent with prior results, Heat's vaccine platform to provide
protection against COVID-19, the ability to enroll patients and
complete the clinical trials on time and achieve desired results
and benefits, especially in light of COVID-19, Heat's ability to
obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to Heat's ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, Heat's
ability to maintain its license agreements, the continued
maintenance and growth of its patent estate, its ability to
establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, its ability to continue to maintain its
listing on the Nasdaq Capital Market and its ability to retain its
key scientists or management personnel, and the other factors
described in Heat's most recent annual report on Form 10-K filed
with the SEC, and other subsequent filings with the SEC. The
information in this release is provided only as of the date of this
release, and Heat undertakes no obligation to update any
forward-looking statements contained in this release based on new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024